BioPharmSignal logoBioPharmSignal

Biotech News

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rigel Pharmaceuticals (RIGL)Rigel PharmaceuticalsCompany update

RIGL (RIGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rigl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IRONDisc Medicine2025-12-06 13:00 EST

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

RIGLRigel Pharmaceuticals2026-05-21 21:17 EST

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

RIGLRigel Pharmaceuticals2026-08-13 12:05 EST

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

APTOAptose Biosciences, Inc.2025-12-06 13:00 EST

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

APTOAptose Biosciences, Inc.2026-06-15 11:30 EST

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

GERNGeron2026-05-12 13:31 EST

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

APVOAptevo Therapeutics2026-05-06 12:05 EST

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

View all latest news

Rigel Pharmaceuticals

Hematology and Oncology Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer. It combines a growing portfolio of marketed medicines with internally developed and licensed clinical programs. TAVALISSE TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune...

Recent company news

RIGLRigel Pharmaceuticals2026-09-02 12:05 EST

Rigel to Participate in Upcoming September Investor Conferences

RIGLRigel Pharmaceuticals2026-08-13 12:05 EST

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

RIGLRigel Pharmaceuticals2026-08-04 20:01 EST

Rigel Reports Second Quarter 2026 Financial Results

RIGLRigel Pharmaceuticals2026-07-28 12:05 EST

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

RIGLRigel Pharmaceuticals2026-07-01 12:05 EST

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

Stock data

Close
46.11 USD
Market cap
555.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States